The study emulated the use of GLP-1 receptor agonists (GLP-1RAs) for primary cardiovascular prevention in a large cohort of over 600,000 individuals. For obese individuals with a high baseline risk (SCORE2 ≥7.5%), the therapy was projected to lower the 10-year cardiovascular disease (CVD) incidence from 13.82% to 10.83%. This represents a significant 22% relative risk reduction and a 2.99% absolute risk reduction, with slightly higher absolute benefits observed in men compared to women.
Introduction: The Evolution of GLP-1 Receptor Agonists
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
